GRI Bio, Inc. (NASDAQ:GRI) Short Interest Update

GRI Bio, Inc. (NASDAQ:GRI) was the recipient of a significant drop in short interest in the month of February. As of February 27th, there was short interest totaling 135,157 shares, a drop of 13.6% from the February 12th total of 156,438 shares. Approximately 10.2% of the company’s shares are short sold. Based on an average daily volume of 59,653 shares, the days-to-cover ratio is currently 2.3 days. Based on an average daily volume of 59,653 shares, the days-to-cover ratio is currently 2.3 days. Approximately 10.2% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on GRI shares. Ascendiant Capital Markets lifted their price target on shares of GRI Bio from $980.00 to $1,008.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Wall Street Zen cut shares of GRI Bio to a “strong sell” rating in a research note on Saturday, January 31st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GRI Bio in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $644.00.

GRI Bio Trading Up 0.8%

Shares of GRI opened at $2.60 on Wednesday. The stock has a market cap of $3.76 million, a P/E ratio of -0.01 and a beta of -1.38. GRI Bio has a 1 year low of $2.10 and a 1 year high of $311.36. The stock’s 50-day moving average price is $3.73 and its two-hundred day moving average price is $29.20.

GRI Bio (NASDAQ:GRI) last announced its quarterly earnings results on Friday, January 30th. The company reported $23.52 earnings per share for the quarter. As a group, equities analysts forecast that GRI Bio will post -3.04 EPS for the current year.

GRI Bio Company Profile

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.